STOCK TITAN

Rocket Pharma ex-officer to sell 6,897 shares

Former officer John Militello filed a Rule 144 notice to sell 6,897 RCKT shares from recently vested restricted stock, including shares to cover related tax obligations.

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. (RCKT) has a notice under Rule 144 filed on behalf of former officer John Militello for the proposed sale of 6,897 shares of common stock through Fidelity Brokerage Services LLC. These shares were acquired on September 11, 2026 through restricted stock vesting as compensation.

The filing also lists Militello’s sales of Rocket Pharmaceuticals common stock over the prior three months, and notes that the sale includes shares needed to cover a tax obligation arising from the settlement of a vested equity award distribution.

Positive

  • None.

Negative

  • None.
Shares proposed to be sold 6,897 shares Common stock under Rule 144 through Fidelity Brokerage Services LLC
Aggregate market value of proposed sale $22,730.44 Value associated with the 6,897 shares of common stock
Shares sold August 18, 2026 1,252 shares Common stock sold for $4,233.51 in the past three months
Proceeds August 18, 2026 sale $4,233.51 Sale of 1,252 common shares
Shares sold September 11, 2026 8,923 shares Common stock sale disclosed for the prior three months
Proceeds September 11, 2026 sale $30,367.65 Sale of 8,923 common shares
Shares sold September 14, 2026 6,857 shares Common stock sale disclosed for the prior three months
Proceeds September 14, 2026 sale $22,730.96 Sale of 6,857 common shares
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock Vesting financial
"Common | 09/11/2026 | Restricted Stock Vesting | Issuer"
Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.
equity award distribution financial
"settlement of a vested equity award distribution."
attorney-in-fact regulatory
"as attorney-in-fact for John Militello"
An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ROCKET PHARMACEUTICALS, INC. (RCKT)?

It discloses that former officer John Militello plans to sell 6,897 shares of Rocket Pharmaceuticals common stock under Rule 144 through Fidelity Brokerage Services LLC, from shares acquired via restricted stock vesting on September 11, 2026.

How many RCKT shares are proposed to be sold in this Form 144?

The notice covers a proposed sale of 6,897 shares of Rocket Pharmaceuticals common stock, with an aggregate market value shown as $22,730.44 as part of the Rule 144 filing.

What is the source of the RCKT shares being sold by John Militello?

The 6,897 shares proposed for sale were acquired on September 11, 2026 via restricted stock vesting from Rocket Pharmaceuticals as compensation, according to the Rule 144 notice.

What past three-month RCKT stock sales by John Militello are reported?

The filing lists sales of 1,252 shares for $4,233.51 on August 18, 2026, 8,923 shares for $30,367.65 on September 11, 2026, and 6,857 shares for $22,730.96 on September 14, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

Keep reading